2. Isotope-Labeled Compounds
  3. Research Area
  4. Deuterated Drug

Deuterated Drug

Deuterated drugs are drugs obtained by replacing hydrogen atoms at specific sites on drug molecules with deuterium atoms. In theory, incorporating ‘heavy hydrogen’ into small molecules improves the half-life of a drug and its toxicity profile. In April 2017, the U.S. Food and Drug Administration (FDA) approved the world’s first deuterated drug, the Deutetrabenazine for the treatment of Huntington’s-disease-related movement disorders. In 2022, the FDA approved another new deuterated drug, Deucravacitinib which is widely used to treat a variety of autoimmune diseases, including classic Sjogren's syndrome, rheumatoid arthritis, and psoriasis[1][2]

The following aspects are considered in the development of deuterated drugs design[2]：

 

Figure 1. Deuteration in Drug Design

 

References:

[1] Nat Biotechnol. 2017, Jun 7; 35(6):493-494.

[2] J.Med.Chem, 2019,62,5276-5297.

Deuterated Drug (9):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10201S
    Sorafenib-d3 1130115-44-4 99.57%
    Sorafenib-d3 (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Sorafenib-d<sub>3</sub>
  • HY-19939S
    VX-984 1476074-39-1 98.86%
    VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium.
    VX-984
  • HY-131968
    BMS-986202 1771691-34-9 99.92%
    BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium.
    BMS-986202
  • HY-145119AS
    Mindeudesivir hydrobromide 2779498-79-0 99.46%
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
    Mindeudesivir hydrobromide
  • HY-50856S
    Deuruxolitinib 1513883-39-0 99.18%
    Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).
    Deuruxolitinib
  • HY-160144S
    Lomedeucitinib 2328068-29-5
    Lomedeucitinib (BMS-986322) is act by targeting receptor tyrosine protein kinase (TYK2). Lomedeucitinib can be used for the research of plaque psoriasis.
    Lomedeucitinib
  • HY-160219S
    BTK-IN-33 2765854-31-5
    BTK-IN-33 is a Btk inhibitor with anticancer effects (WO2023174300A1; compound I).
    BTK-IN-33
  • HY-13017S
    Ivacaftor-d9 1413431-07-8 99.83%
    Ivacaftor-d9 is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research[1].
    Ivacaftor-d<sub>9</sub>
  • HY-B0590S
    Tetrabenazine-d6 1392826-25-3 ≥99.0%
    Tetrabenazine-d6 (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590), is the first deuterium approved worldwide for the research of Huntington's disease, or other hyperkinetic movement disorders.
    Tetrabenazine-d<sub>6</sub>